Recalls for Soliris (eculizumab)

Alexion Initiates Voluntary Nationwide Recall of Certain Lots of SolirisĀ® (eculizumab) Concentrated Solution for Intravenous Infusion Due to the Presence of Visible Particulate Matter in a Single Lot
06/02/2014 Food Recall

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that it is initiating a voluntary recall of certain lots of SolirisĀ® (eculizumab) 300 mg/30 mL concentrated solution for intravenous infusion that were manufactured using a process component during vial filling identified in the November 2013 recall to the hospital/user level. As previously stated, Alexion believes that it has identified the process component that resulted in the presence of the visible particles and implemented a change to the process.

  • Company:
    Alexion Pharmaceuticals, Inc.
  • Problem
    Suffocation And Choking Hazards